The correlation between immunohistochemical expression of MMP-2 and the prognosis of epithelial ovarian cancer

Ginekologia Polska

Volumn 85, Issue 2, 2014, Pages 121-130

  Ekinci, Tekin ^a   Özbay, Pelin Özun ^b   Yiǧit, Seyran ^c   Yavuzcan, Ali ^d   Uysal, Selda ^c   Soylu, Ferit ^c  

^a Kozluk State Hospital   (Turkey)

^b Dogubeyazit State Hospital   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d DUZCE UNIVERSITY   (Turkey)

Author keywords

Epithelial ovarian cancer; Immunohistochemical expression; MMP 2; Prognosis

Indexed keywords

GELATINASE A;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMISTRY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PROGNOSIS; TURKEY (REPUBLIC); WOMEN'S HEALTH;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; TURKEY; WOMEN'S HEALTH;

EID: 84897553147     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/1702     Document Type: Article

References (24)

1. Yavuzcan A, Baloglu A, Cetinkaya B. The investigation of the factors affecting retroperitoneal lymph node metastasis in stage IIIC and IV epithelial ovarian cancer. Arch Gynecol Obstet. 2009, 280, 939-944.
2. Piver MS, Baker TR, Piedmonte M, [et al.]. Epidemiology and etiology of ovarian cancer. Semin Oncol. 1991, 18, 177-185.
3. Nowak-Markwitz E, Pula B, Szajnik M, [et al.]. Expression of survivin, SDF-1 and CXCR4 on tumor cells in ovarian cancer. Ginekol Pol. 2010, 81, 674-677.
4. Crum CP, Lee KR. Diagnostic Gynecologic and Obstetric Pathology. 2nd ed. Philadelphia: Elsevier Saunders. 2006, 24-28, 793-838.
5. Yu WH, Woessner JFJr, McNeish JD, Stamenkovic T. CD44 anchors the assembly of matrilysin/ MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 2002, 16, 307-323.
6. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001, 17, 463-516.
7. Kamat AA, Fletcher M, Gruman LM, [et al.]. The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2006, 12, 1707-1714.
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002, 2, 161-174.
9. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001, 357, 539-545.
10. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004, 4, 71-78.
11. Kamel H, Abdelazim I, Habib SM, [et al.]. Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours. J Obstet Gynaecol Can. 2010, 32, 580-586.
12. Périgny M, Bairati I, Harvey I, [et al.]. Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol. 2008, 129, 226-231.
13. Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, [et al.]. Matrix metalloproteinase-2 (MMP-2) and-9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res. 2007, 27, 2753-2758.
14. De Nictolis M, Garbisa S, Lucarini G, [et al.]. 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study. Int J Gynecol Pathol. 1996, 15, 102-109.
15. Campo E, Merino MJ, Tavassoli FA, [et al.]. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol. 1992, 16, 500-507.
16. Sakata K, Shigemasa K, Uebaba Y, [et al.]. Expression of matrix metalloproteinases-2 and-9 by cells isolated from the peritoneal fluid of women with ovarian carcinoma. Acta Cytol. 2002, 46, 697-703.
17. Torng PL, Mao TL, Chan WY, [et al.]. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinomaprogression. Gynecol Oncol. 2004, 92, 559-567.
18. Schmalfeldt B, Prechtel D, Härting K, [et al.]. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001, 7, 2396-2404.
19. Davidson B, Goldberg I, Gotlieb WH, [et al.].The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol. 2002, 187, 39-45.
20. Westerlund A, Apaja-Sarkkinen M, Höyhtyä M, [et al.]. Gelatinase A-immunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer. Gynecol Oncol. 1999,75, 91-98.
21. Wu X, Li H, Kang L, [et al.]. Activated matrix metalloproteinase-2--a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol. 2002, 84, 126-134.
22. Garzetti GG, Ciavattini A, Lucarini G,[et al.]. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res. 1995, 15, 2799-2804.
23. Vihinen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002, 99, 157-166.
24. Hirte H, Vergote IB, Jeffrey JR, [et al.]. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol. 2006, 102, 300-308.